Mitochondrial cofactor supplement

Coenzyme Q10

Coenzyme Q10's elimination half-life is about 33 hours in a pharmacokinetic review, the same as the app's figure of 33 hours.1

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Coenzyme Q10 after one dose: 50% at ~33 h, 25% at 66 h, 12.5% at 99 h.

Drawn from the half-life in the app's model, ~33 h. The model's figures

Coenzyme Q10 (CoQ10) is, in the words of one safety review, "a naturally occurring component present in living cells" whose function is "an essential cofactor for ATP production".2 The authors of that review list the Functional Food Ingredients Division of Kaneka Corporation, Osaka, Japan, as their affiliation.2 Mortensen and colleagues write in a sub-group analysis of the Q-SYMBIO trial that CoQ10 "is primarily synthesized endogenously and in sufficient amounts during normal physiological conditions" and that "endogenous production of CoQ10 declines with age".3 The app lists coenzyme Q10 as an oral supplement in the subcategory Mitochondrial Cofactor. Two forms exist, ubiquinone (oxidised) and ubiquinol (reduced), which the body interconverts according to the app's note. In a randomised crossover trial of 21 healthy adults aged 65 to 74, Pravst and colleagues (Nutrients, 2020) report that "CoQ10 appeared in the blood mostly as ubiquinol, even if consumed as ubiquinone".4 The app grades the evidence for coenzyme Q10 as moderate.

2

How it works

Mortensen and colleagues ascribe the efficacy of CoQ10 in heart failure "primarily" to "its important role as electron carrier in the electron transport chain and strong anti-oxidative properties".3 The app's note places CoQ10 synthesis in the mevalonate pathway, the pathway statins block. Qu and colleagues (European Journal of Medical Research, 2018) write that "The mechanisms of the reduction of circulating CoQ10 following statin treatment remain unclear though some hypotheses have been offered".5 One hypothesis they give is that "Farnesyl pyrophosphate, a precursor in the synthesis of CoQ10, was blocked during statin treatment, which might contribute to a reduction of circulating/intramuscular CoQ10".5

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~33 h
Bioavailability
5%
Typical dose
100–300 mg/day
Route
Oral
Time to peak
~6 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics3 rows
ParameterApp's figureReported in the sources
Half-life~33 hAbout 33 h in a pharmacokinetic review by Bhagavan and Chopra (Free Radical Research, 2006)1
Time to peak~6 hAround 6 h in the same review; median 12 h in each of three formulations, with a range of 3 to 48 h for the water-soluble syrup and 2 to 48 h for the ubiquinone and ubiquinol capsules, after a single dose equivalent to 100 mg in 21 healthy adults aged 65 to 74 (Pravst and colleagues, 2020)1,4
Bioavailability5%No measured absolute figure appears in the records read; the review states that "absorption of dietary CoQ10 is slow and limited"; the app's own note calls its 5% a modelled value, not a measured one1

Bhagavan and Chopra also give "reference intervals for plasma CoQ10 range from 0.40 to 1.91 micromol/l in healthy adults" and report "reasonable correlation between increase in plasma CoQ10 and ingested dose up to a certain point".1 The first author of that review lists Tishcon Corporation, Westbury, NY, as an affiliation.1 The app uses a one-compartment model. Pravst and colleagues gave 21 healthy adults aged 65 to 74 a single dose of three formulations, each equivalent to 100 mg of CoQ10, with a one-week washout, and followed plasma for 48 hours.4 Against ubiquinone capsules, the water-soluble syrup gave a bioavailability "2.4-fold higher (95% CI: 1.3-4.5; p = 0.002)", while ubiquinol capsules were "not significantly increased (1.7-fold; 95% CI: 0.9-3.1, p = 0.129)".4 That trial was funded by the Slovenian Research Agency and Valens Int. d.o.o., the company named for the water-soluble syrup, and its authors declare no conflicts of interest.4

4

Human studies

Table 4.1Human studies8 rows
Study and yearDesignPeopleDose and lengthMain result
Mortensen SA and colleagues, Q-SYMBIO, JACC: Heart Failure 20146Randomised, double-blind, multicentre trial, add-on to standard therapy, placebo comparator6420 patients with moderate to severe chronic heart failure6CoQ10 100 mg 3 times daily or placebo; 2 years6Primary long-term endpoint (major adverse cardiovascular events) reached by 15% on CoQ10 and 26% on placebo (hazard ratio 0.50; 95% CI 0.32 to 0.80; p = 0.003); "no significant changes in short-term endpoints"6
Mortensen AL and colleagues, Q-SYMBIO European sub-group, Cardiology Journal 20193Post-hoc sub-group analysis of the randomised trial; grant from the International Coenzyme Q10 Association3231 patients from 14 centres in 6 European countries (108 CoQ10, 123 placebo)3CoQ10 300 mg daily (Ubiquinone, Pharma Nord ApS) or placebo; 2 years3Major adverse cardiovascular events in 10 (9%) on CoQ10 and 33 (27%) on placebo (hazard ratio 0.23; 95% CI 0.11–0.51); no changes from baseline in the specified short-term endpoints; adverse events 17 (16%) against 28 (23%), p = 0.1883
Claxton and colleagues, Health Technology Assessment 20227Systematic review and meta-analysis of randomised trials of CoQ10 plus standard care against standard care alone in chronic heart failure; NIHR-funded726 trials, 2250 participants7Doses and lengths varied by trial; not summarised in the record read7All-cause mortality: relative risk 0.68 (95% CI 0.45 to 1.03; seven trials, 1371 participants), described as "a possible benefit"; short-term functional outcomes "more modest or unclear"7
Banach and colleagues, Mayo Clinic Proceedings 20158Meta-analysis of randomised controlled trials; CoQ10 against control in statin-treated people86 studies, 302 patients receiving statin therapy; 5 studies with 253 participants for muscle pain and 5 studies with 226 participants for plasma creatine kinase8Doses varied; no dose-effect association reported8Muscle pain: standardised mean difference -0.53 (95% CI -1.33 to 0.28; P=.20); plasma creatine kinase: mean difference 11.69 U/L (95% CI -14.25 to 37.63; P=.38)8
Qu and colleagues, Journal of the American Heart Association 20189Meta-analysis of randomised controlled trials, CoQ10 against placebo912 trials, 575 patients (294 CoQ10, 281 placebo); trial sizes 37 to 769100–600 mg/day; 30 days to 3 months9Muscle pain: weighted mean difference −1.60 (95% CI −1.75 to −1.44); plasma creatine kinase: 0.09 (95% CI −0.06 to 0.24; P=0.23)9
Kennedy and colleagues, Atherosclerosis 202010Systematic review and meta-analysis of randomised trials of oral CoQ10 against placebo107 studies, 321 adults with statin-associated myalgia10Doses not summarised in the record read; studies published 2007 to 201610Myalgia: weighted mean difference -0.42 (95% CI -1.47 to 0.62); remaining on statin: relative risk 0.99 (95% CI 0.81 to 1.20)10
Kovacic and colleagues, Journal of Nutritional Science 202511Systematic review and meta-analysis of randomised controlled trials117 trials, 389 statin-treated adults (35 to 76 per trial)11100 to 600 mg per day; 30 to 90 days11Pain intensity: weighted mean difference −0.96 (95% CI −1.88 to −0.03); significant reduction in four trials, no significant change in three11
Pravst and colleagues, Nutrients 20204Randomised, three-period crossover, single dose, one-week washout; funded in part by the maker of the water-soluble product421 healthy adults aged 65 to 744Three formulations each equivalent to 100 mg CoQ10; plasma followed 48 h4Relative to ubiquinone capsules, water-soluble syrup 2.4-fold (95% CI 1.3 to 4.5; p = 0.002); ubiquinol capsules 1.7-fold, not significant (95% CI 0.9 to 3.1; p = 0.129)4

Deeper analysis: Q-SYMBIO

Mortensen SA and colleagues, at Copenhagen University Hospital with centres in several countries, reported Q-SYMBIO in JACC: Heart Failure in 2014.6 The authors state that "Previous randomized controlled trials of CoQ10 in HF were underpowered to address major clinical endpoints".6 In the design, short-term endpoints at 16 weeks were changes in New York Heart Association class, the 6-minute walk test and N-terminal pro-B type natriuretic peptide, and the primary long-term endpoint at 2 years was "composite major adverse cardiovascular events as determined by a time to first event analysis".6 Of 420 patients enrolled, 15% on CoQ10 and 26% on placebo reached the primary long-term endpoint (hazard ratio 0.50; 95% CI 0.32 to 0.80; p = 0.003), while "There were no significant changes in short-term endpoints".6 Secondary endpoints named as significantly lower with CoQ10 were cardiovascular mortality (9% against 16%, p = 0.026), all-cause mortality (10% against 18%, p = 0.018) and hospital stays for heart failure (p = 0.033), with NYHA class improved after 2 years (p = 0.028).6 The authors conclude that "Long-term CoQ10 treatment of patients with chronic HF is safe, improves symptoms, and reduces major adverse cardiovascular events".6 The trial is registered as ISRCTN94506234; searches of ClinicalTrials.gov for Q-SYMBIO and for coenzyme Q10 in heart failure returned no entries.6 The PubMed record for the 2014 paper lists the publication type "Research Support, Non-U.S. Gov't"; its funding statement, author disclosures, adverse event counts, withdrawals and limitations section were not in the record read, because the full text is not in PubMed Central.6 Mortensen AL and colleagues describe their 2019 sub-group analysis as "post-hoc" and write that "The present study was not powered to assess between-population differences".3 They note the main trial group of 420 "included 231 patients from Europe, 178 patients from Asia and 11 patients from Australia", and that 57% of the European sub-group took statins against 36% in the total population.3 The sub-group paper adds that serum CoQ10 in the treated total population "decreased from 3.01 ± 0.17 μg/mL at 3 months to 2.01 ± 0.20 μg/mL at 2 years", which the authors say "could indicate a problem with compliance in the non-European patient population towards the end of the study period".3 The sub-group paper reports a grant from the International Coenzyme Q10 Association, "a non-profit association formed in 1997 to promote research and educational activities related to CoQ10", and "Conflict of interest: None declared".3

Deeper analysis: the 2022 systematic review of heart failure trials

Claxton and colleagues at the Centre for Reviews and Dissemination, University of York, and collaborators searched databases up to March 2020 and included "26 trials, comprising 2250 participants".7 They write that "Many trials were reported poorly and were rated as having a high or unclear risk of bias in at least one domain".7 For all-cause mortality the relative risk was 0.68 (95% CI 0.45 to 1.03) across seven trials and 1371 participants, an interval that includes 1.7 They report "no indication of increased adverse events with coenzyme Q10" and that "Meta-regression found no evidence of treatment interaction with statins".7 Their stated limitations include that "For most outcomes, data were available from few trials and different trials contributed to different outcomes" and that a lack of individual participant data meant planned effect-modifier analyses were not possible.7 Their conclusion cites "important concerns about risk of bias, plausibility of effect sizes and applicability of the evidence base".7 The project was funded by the National Institute for Health Research Health Technology Assessment programme.7

Deeper analysis: meta-analyses of statin muscle symptoms

Four meta-analyses of randomised trials give different answers on whether CoQ10 changes muscle symptoms in statin-treated people, and they pooled different sets of trials (6, 7, 7 and 12).8,10,11,9 Banach and colleagues (Mayo Clinic Proceedings, 2015) searched MEDLINE, the Cochrane Library, Scopus and EMBASE to May 2014 and concluded that the results "do not suggest any significant benefit of CoQ10 supplementation in improving statin-induced myopathy", adding that "Larger, well-designed trials are necessary".8 The PubMed record for Banach and colleagues carries no funding or conflict-of-interest statement.8 Qu and colleagues (Journal of the American Heart Association, 2018) reported that CoQ10 "ameliorated statin-associated muscle symptoms", but not plasma creatine kinase, with significant heterogeneity for muscle pain (I2=89.6%) and for creatine kinase (I2=80.3%).9 Their stated limitations were that "there were only few eligible RCTs, and most of them included relatively small populations" and that "the eligible studies were heterogeneous".9 That work was supported by Chinese national research funds, and the authors declare no competing interests.9 Kennedy and colleagues (Atherosclerosis, 2020) write that "Only two of these studies demonstrated a positive effect of CoQ10 therapy in relieving muscle pain" and that the pooled analysis did not show benefit for myalgia (weighted mean difference -0.42; 95% CI -1.47 to 0.62) or for remaining on statin therapy (relative risk 0.99; 95% CI 0.81 to 1.20).10 One Kennedy author lists Roche Diagnostics (Schweiz) AG, Rotkreuz, Switzerland, as an affiliation, and the authors declared they did not have anything to disclose regarding conflict of interest.10 Kovacic and colleagues (Journal of Nutritional Science, 2025) searched Medline and the Cochrane Library in August 2024 and found a pooled pain-intensity difference of −0.96 (95% CI −1.88 to −0.03), with "a significant reduction of SAMS in four trials and no significant change in three trials".11 Their own caveats are that "meta-regression with less than 10 studies is not recommended and results need to be interpreted with caution", that "the overall effect size of the meta-analysis varies with study selection", and that "More research is needed for evidence-based recommendations".11 Kovacic and colleagues report financial support from the Society for Applied Vitamin Research (GVF, Jena, Germany) and declare no conflict of interest.11 In the same paper, the subgroup of studies with statin-associated muscle symptoms as an inclusion criterion showed a non-significant reduction in mean pain score, and the authors conclude that the results are limited due to small sample sizes and a high heterogeneity.11 A separate meta-analysis by Qu and colleagues (European Journal of Medical Research, 2018) of 12 randomised trials with 1776 participants reported that statin treatment lowered circulating CoQ10 (standardised mean difference - 2.12; 95% CI - 3.40 to - 0.84; p = 0.001) and noted potential publication bias.5

5

Doses reported in studies and on labels

The app lists a typical dose of 100 to 300 mg/day by mouth.

Table 5.1Doses reported in studies and on labels7 rows
SourceSetting and comparatorDose and routeLengthn
Q-SYMBIO, Mortensen SA and colleagues 20146Chronic heart failure; placebo; add-on to standard therapy6CoQ10 100 mg 3 times daily; route not stated in the record read62 years4206
Q-SYMBIO European sub-group, Mortensen AL and colleagues 20193Chronic heart failure; placebo3CoQ10 300 mg daily (Ubiquinone, Pharma Nord ApS)32 years2313
Meta-analysis, Qu and colleagues 20189Statin-associated muscle symptoms; placebo9100–600 mg/d930 days to 3 months5759
Meta-analysis, Kovacic and colleagues 202511Statin-treated adults; four of the seven studies named statin-associated muscle symptoms as an inclusion criterion; comparable control group11100 to 600 mg per day1130 to 90 days38911
Pravst and colleagues 20204Healthy adults aged 65 to 74; crossover against other formulations4Single dose equivalent to 100 mg CoQ10 in each formulation4Single dose; 48 h follow-up214
Observed safe level, Hathcock and Shao 200612Risk assessment of clinical trial data; not a trialUp to 1200 mg/day (intake level)12Not applicableNot applicable
Acceptable daily intake, Hidaka and colleagues 20082Derived from a 52-week rat toxicity study and clinical data; not a trial in people12 mg/kg/day, i.e. 720 mg/day for a person weighing 60 kg; observed safety level 1200 mg/day/person2Not applicableNot applicable

A DailyMed search for coenzyme Q10 returned 13 labels, each a multi-ingredient product or a cosmetic mask; no single-ingredient coenzyme Q10 label with a stated dose was identified.

In the Q-SYMBIO European sub-group, "There were no differences in the total number of adverse events in the CoQ10 group, 17 (16%) vs. 28 (23%) in the placebo group (p = 0.188)".3 Claxton and colleagues report "no indication of increased adverse events with coenzyme Q10" across their included heart failure trials.7 Hathcock and Shao write that "Reports of nausea and other adverse gastrointestinal effects of CoQ10 cannot be causally related to the active ingredient because there is no dose-response relationship: the adverse effects are no more common at daily intakes of 1200 mg than at a 60 mg".12 The first author of that risk assessment lists the Council for Responsible Nutrition as an affiliation.12 Hidaka and colleagues conclude that CoQ10 "has low toxicity and does not induce serious adverse effects in humans" on the basis of published safety reports.2 Landbo and Almdal (Ugeskrift for Laeger, 1998) describe "a 72-year-old female treated with warfarin" who "showed less responsiveness to warfarin than previously" after taking CoQ10, with responsiveness the same as before once it was stopped.13 The case report's authors suggest that "Coenzyme Q10 is chemically similar to K-vitamins, which may explain the interaction with warfarin" and note that an interaction "has previously been reported".13 Engelsen, Nielsen and Winther (Thrombosis and Haemostasis, 2002) published a letter titled as "A randomised, double blind, placebo-crossover trial" of CoQ10 and Ginkgo biloba on warfarin dosage; the PubMed record read holds no summary text, so its result is not stated here.14

The app lists lipids and blood pressure as markers to monitor. In the Q-SYMBIO European sub-group, "For heart rate and blood pressure there were no significant changes from baseline with treatment in either group nor were there any between-group differences".3 That sub-group consisted of people with moderate to severe heart failure given 300 mg daily or placebo on top of standard therapy.3 The same sub-group reports serum CoQ10 that "remained constant and above 3 μg/mL throughout the study period" on treatment.3 Plasma creatine kinase did not differ between CoQ10 and placebo in the meta-analyses of Banach and colleagues (mean difference 11.69 U/L; 95% CI -14.25 to 37.63) and Qu and colleagues (weighted mean difference 0.09; 95% CI −0.06 to 0.24).8,9 Statin treatment lowered circulating CoQ10 in a meta-analysis, and the authors state it "was not associated with the statin solution, intensity, or treatment time".5 The app's note records case reports of reduced warfarin effect, and the 1998 case report describes reduced responsiveness to warfarin that returned to the earlier level after CoQ10 was stopped.13 None of the records read reports a blood lipid outcome for CoQ10, so no lipid result is given here.

8

Regulatory and anti-doping status

The app's note states that coenzyme Q10 is not WADA prohibited. A text search of the World Anti-Doping Agency 2026 Prohibited List document read found no entry for coenzyme Q10, ubiquinone or ubiquinol.15 Hidaka and colleagues write that "In most countries, CoQ10 has been widely used as a dietary supplement for more than 20 years".2 Claxton and colleagues, writing about the United Kingdom's National Health Service, note that "coenzyme Q10 has not been subject to the scrutiny of drug-licensing processes".7

No measured absolute oral bioavailability for CoQ10 appeared in the records read, and the app's 5% is described in its own note as modelled. The full text of the 2014 Q-SYMBIO paper, including its funding, adverse events and limitations, was not available in the records read. Claxton and colleagues write that "A new independent, well-designed clinical trial" in a typical UK heart failure population "may be warranted".7 Meta-analyses of statin muscle symptoms disagree, and the sources read do not settle why beyond different sets of trials and heterogeneity.8,9,10,11 The one formulation trial read found ubiquinol capsules "not significantly increased" in bioavailability against ubiquinone capsules, and no trial comparing clinical outcomes of ubiquinol with ubiquinone was identified.4

What is the half-life of coenzyme Q10?

A pharmacokinetic review gives an elimination half-life of about 33 hours, the same as the app's figure of 33 hours.1

How long does coenzyme Q10 take to reach its peak level?

The same review gives a time to peak of around 6 hours, and the app lists about 6 hours.1 A single-dose trial in 21 healthy adults aged 65 to 74 reported a median time to peak of 12 hours for each of three formulations, with a range of 3 to 48 hours for the water-soluble syrup and 2 to 48 hours for the ubiquinone and ubiquinol capsules.4

What is the bioavailability of coenzyme Q10?

The app lists 5%, which its own note describes as a modelled value, not a measured one. Bhagavan and Chopra state that "absorption of dietary CoQ10 is slow and limited".1

Is coenzyme Q10 banned by WADA?

The app's note says it is not WADA prohibited. A text search of the 2026 Prohibited List document read found no entry for coenzyme Q10, ubiquinone or ubiquinol.15

What was the Q-SYMBIO trial of coenzyme Q10?

Q-SYMBIO was a randomised, double-blind trial in 420 patients with moderate to severe chronic heart failure, comparing CoQ10 100 mg 3 times daily with placebo for 2 years.6 Its primary long-term endpoint was reached by 15% on CoQ10 and 26% on placebo (hazard ratio 0.50; 95% CI 0.32 to 0.80), with no significant changes in short-term endpoints.6 A 2022 systematic review of 26 heart failure trials gave a relative risk for all-cause mortality of 0.68 (95% CI 0.45 to 1.03) across seven trials and 1371 participants, an interval that includes 1.7

Does coenzyme Q10 reduce statin muscle symptoms?

Meta-analyses disagree: Banach and colleagues (2015) and Kennedy and colleagues (2020) reported no significant benefit, while Qu and colleagues (2018) and Kovacic and colleagues (2025) reported a significant reduction in muscle symptoms.8,10,9,11

Do statins lower coenzyme Q10 levels?

A meta-analysis of 12 randomised trials with 1776 participants reported that statin treatment lowered circulating CoQ10 (standardised mean difference - 2.12; 95% CI - 3.40 to - 0.84).5 The authors note potential publication bias and that the mechanisms "remain unclear".5

Does coenzyme Q10 interact with warfarin?

A 1998 Danish case report describes a 72-year-old woman on warfarin who "showed less responsiveness to warfarin than previously" while taking coenzyme Q10.13 A randomised, double-blind, placebo-crossover trial of CoQ10 and Ginkgo biloba on warfarin dosage exists, but the PubMed record read holds no result.14

What is the difference between ubiquinone and ubiquinol?

Ubiquinone is the oxidised form and ubiquinol the reduced form, and the body interconverts them, according to the app's note. In a crossover trial, ubiquinol capsules were "not significantly increased" in bioavailability against ubiquinone capsules (1.7-fold; 95% CI 0.9 to 3.1; p = 0.129).4 CoQ10 "appeared in the blood mostly as ubiquinol, even if consumed as ubiquinone".4

What side effects of coenzyme Q10 are reported?

In the Q-SYMBIO European sub-group, adverse events were reported by 17 (16%) on CoQ10 and 28 (23%) on placebo, p = 0.188.3 Hathcock and Shao state that gastrointestinal reports such as nausea were "no more common at daily intakes of 1200 mg than at a 60 mg".12

12

References

  1. Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 2006. PMID 16551570
  2. Hidaka T, et al. Safety assessment of coenzyme Q10 (CoQ10). BioFactors 2008. PMID 19096117
  3. Mortensen AL, et al. Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiol J 2019. PMC8086660
  4. Pravst I, et al. Comparative bioavailability of different coenzyme Q10 formulations in healthy elderly individuals. Nutrients 2020. PMC7146408
  5. Qu H, et al. The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials. Eur J Med Res 2018. PMC6230224
  6. Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail 2014. PMID 25282031
  7. Claxton L, et al. Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation. Health Technol Assess 2022. PMID 35076012
  8. Banach M, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015. PMID 25440725
  9. Qu H, et al. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc 2018. PMC6404871
  10. Kennedy C, et al. Effect of coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: a systematic review and meta-analysis. Atherosclerosis 2020. PMID 32179207
  11. Kovacic S, et al. Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis. J Nutr Sci 2025. PMC12554813
  12. Hathcock JN, Shao A. Risk assessment for coenzyme Q10 (ubiquinone). Regul Toxicol Pharmacol 2006. PMID 16814438
  13. Landbo C, Almdal TP. Interaction between warfarin and coenzyme Q10 (in Danish). Ugeskr Laeger 1998. PMID 9621803
  14. Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. Thromb Haemost 2002. PMID 12083489
  15. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list